Increased Transforming Growth Factor β1 Plasma Level in Patients with Renal Cell Carcinoma:A Tumor-Specific Marker?

Publisher： Karger

E-ISSN： 1423-0399|60|4|205-207

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.60, Iss.4, 1998-08, pp. : 205-207

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Plasma fibrinogen level: an independent prognostic factor for disease‐free survival and cancer‐specific survival in patients with localised renal cell carcinoma

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 598-603

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hepatocyte nuclear factor‐1β is not a specific marker of clear cell carcinoma in serous effusions

By  

CANCER CYTOPATHOLOGY, Vol. 122, Iss. 2, 2014-02 ,pp. : 153-158

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1269-1283

John Wiley & Sons Inc

Access to resources Recommend Favorite

Coordinated Increase in Serum Platelet-Derived Growth Factor-BB and Transforming Growth Factor-β1 in Patients with Chronic Pancreatitis

By  

Pancreatology, Vol. 11, Iss. 4, 2011-09 ,pp. : 434-440

Karger

Access to resources Recommend Favorite

Fibroblast Growth Factor Receptor 1 as a Target for the Therapy of Renal Cell Carcinoma

By  

Oncology, Vol. 88, Iss. 6, 2015-0 ,pp. : 321-331

Karger

Access to resources Recommend Favorite